Advertisement

Topics

Search Results for "President CEO Epicentre Biotechnologies"

22:41 EDT 24th September 2017 | BioPortfolio

Matching Channels

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Matching News

Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference

SAN CARLOS, CA--(Marketwired - May 30, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) ...

DGAP-HV: Elanix Biotechnologies AG: -4-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

DGAP-HV: Elanix Biotechnologies AG: -2-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

DGAP-HV: Elanix Biotechnologies AG: -6-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

DGAP-HV: Elanix Biotechnologies AG: -3-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

DGAP-HV: Elanix Biotechnologies AG: -5-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

Fujifilm Diosynth Biotechnologies opens new UK lab

Fujifilm Diosynth Biotechnologies has opened a $9m process development laboratory in Teeside, UK.

Lion Biotechnologies changes name to Iovance Biotherapeutics

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies t...

Matching PubMed Articles

Being SAM President - A Long Journey in a Short Time.

My first piece of advice for all aspiring medical leaders would be this, 'don't bother' with a leadership course, as nothing can fully prepare you for the role. That said, please continue reading as I...

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.

Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was t...

The US President's Malaria Initiative and under-5 child mortality in sub-Saharan Africa: A difference-in-differences analysis.

Despite substantial financial contributions by the United States President's Malaria Initiative (PMI) since 2006, no studies have carefully assessed how this program may have affected important popula...

Maintaining US Leadership in Emerging Biotechnologies to Grow the Economy of the Future.

Pence, Putin, Mbeki and Their HIV/AIDS-Related Crimes Against Humanity: Call for Social Justice and Behavioral Science Advocacy.

Indiana, a large rural state in the Midwestern United States, suffered the worst North American HIV outbreak among injection drug users in years. The Indiana state government under former Governor and...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement